Dr. Allison Goldfine completed her medical school training at the University of Pennsylvania, and internship and residency in Internal Medicine at the University of Massachusetts Medical Center. She did her fellowship training in endocrinology and diabetes at the Joslin Diabetes Center where she is now Co-Head, Section of Clinical Research, and Associate Professor of Medicine, Harvard Medical School. Her research focuses on identification of pathways relevant to development of type 2 diabetes, and/or cardiometabolic complications of the disease, and in trials to develop new treatment strategies. She has performed multiple physiology studies to reveal underlying biology, and participated in the steering committee to lead multicenter clinical trials targeting inflammation using salsalate to lower glycemia in prediabetes and type 2 diabetes, and to reduce coronary artery plaque progression. She participate on and leads Data Safety Monitoring Trials for ongoing industry and NIH sponsored trials. She recently completed term as a voting member on the Endocrine and Metabolic Disease Advisory Committee to the Food and Drug Administration, has served on the American Diabetes Association Practice Guideline Committee, and now Chairpersons the American Diabetes Association Clinical Research Study Group. At the Joslin, She continues to perform clinical and translational research, provide medical care for patients with diabetes, and teach at Harvard Medical School.
